Population
1 63-year-old woman with Parkinson's disease who developed a neuroleptic malignant syndrome-like state…
Comparison
L-dopa and carbidopa vs Initial 14 days of treatment with intravenous…
Design
Case_report
Authors
Loading...
May support dopaminergic trial in refractory withdrawal states; leaves open confirmation in controlled studies.
L-dopa and carbidopa can effectively treat neuroleptic malignant syndrome-like states induced by the withdrawal of antiparkinsonian drugs, suggesting dopaminergic hypoactivity as a shared underlying mechanism.
Toru et al. (1981) studied this question.